Epidermal growth factor protects against carbon tetrachloride-induced hepatic injury

Clinical Science

Volumn 94, Issue 3, 1998, Pages 219-223

  Berlanga, J ^a   Caballero, M E ^a   Ramirez, D ^b   Torres, A ^c   Valenzuela, C ^a   Lodos, J ^a   Playford, R J ^d  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^c Juan Manuel Marquez Pediatric Hospital   (Cuba)

^d LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cytoprotection; Hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBON TETRACHLORIDE; EPIDERMAL GROWTH FACTOR; LIVER PROTECTIVE AGENT; MALONALDEHYDE; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID PEROXIDATION; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031883392     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0940219     Document Type: Article

References (14)

1. Playford RJ, Marchbank T, Calnan DP, et al. EGF is digested to smaller less active forms in acidic gastric juice. Gastroenterology 1995; 108: 92-101.
2. Jones DE, Tran-Patterson R, Cui DM, et al. Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration. Am J Physiol 1995; 268: G872-8.
3. 4-administered rats. Biochem Pharmacol 1987; 36: 4055-8.
4. Reitman S, Frankel S. A colorimetric method for the determination of serum oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56-63.
5. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978; 90: 37-43.
6. 4-induced ultrastructural changes in rat liver. Br J Exp Pathol 1980; 61: 505-10.
7. González R, Ancheta O, Pascual C, Pellón R, Frutos N, Milián V. Hepatoprotective properties of lobenzarit disodium in the rat. Biotechnol Apl 1991; 8: 140-7.
8. Pascual C, Gonzalez R, Romay C. Drug effects on superoxide generation and chemiluminescence response of human leukocytes. Agents Actions 1991; 32: 277-82.
9. 4. Acta Pharmacol Sin 1997; 18: 176-9.
10. Kiyohara Y, Nishiguchi K, Komada F, et al. Cytoprotective effects of epidermal growth factor (EGF) ointment containing nafamostat, a protease inhibitor, on tissue damage at burn sites in rats. Biol Pharmaceut Bull 1993; 16: 1146-9.
11. Price LT, Chen Y, Frank L. Epidermal growth factor increases antioxidant enzyme and surfactant system development during hyperoxia and protects fetal lungs in vitro from hyperoxic toxicity. Pediatric Res 1993; 34: 577-85.
12. Playford RJ. Peptides and gastrointestinal mucosal integrity. Gut 1995; 37: 595-7.
13. Sullivan PB, Lewindon PJ, Oppenheimer SJ, Cheng C, Goodlad RG, Wright NA. A pilot study of the safety and efficacy of epidermal growth factor in the treatment of necrotiang enterocolitis. Gut 1997; 41 (Suppl. 3): A69.
14. Vinter-Jensen L, Juhl CO, Teglbjaerg PS, Poulsen SS, Dajani EZ, Nexo E. Gastroentercology 1997; 113: 1367-74.